ArticleJournal of advanced research2026
Structural optimization and functional evaluation of cytisine for redox homeostasis regulation in lung cancer cells.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTargeting redox homeostasis represents a promising strategy to selectively eliminate cancer cells through oxidative stress-mediated apoptosis. However, developing specific molecular entities capable of effectively disrupting this balance remains a key challenge.
objectivesThis study aimed to construct a novel library of cytisine derivatives through rational drug design to discover lead compounds with potent redox-disrupting activity and validate their potential as precision therapy candidates for lung cancer.
methodsA focused library of 77 derivatives was designed and synthesized via rational modification of key pharmacophores in cytisine. The antitumor activity and mechanism of action of candidate compounds were evaluated using in vitro cellular models and in vivo animal models.
resultsAmong these, YU-C-ThioU-9 emerged as a lead compound with potent antitumor activity. Mechanistic investigations revealed that YU-C-ThioU-9 disrupts intracellular redox balance, leading to a marked accumulation of reactive oxygen species (ROS) and consequent oxidative damage. This redox perturbation, marked by oxidative stress accumulation, ultimately induces apoptotic cell death in lung cancer cells. Importantly, YU-C-ThioU-9 exhibited robust anticancer efficacy in both in vitro and in vivo models.
conclusionThese findings establish redox disruption as a clinically actionable avenue for precision oncology and position YU-C-ThioU-9 as a lead cytisine-derived candidate for lung cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.